Priovant begins phase 2b/3 trial for brepocitinib in rare scalp disorder

April 2, 2026 5:00 AM

Priovant Therapeutics has initiated a Phase 2b/3 clinical trial for brepocitinib in lichen planopilaris, a rare inflammatory scalp disorder that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found